Peptide Mixing Compatibility Chart

What each answer rests on

The label sentences behind the approved grid, each once. A pair is “do not mix” when either product's label forbids it, even if the other label is silent, and “may mix” only when a label allows it and neither forbids it. Where a mix is allowed (NPH with a mealtime insulin), the labels also say to draw the clear, faster insulin into the syringe first and to inject straight away, and none allows mixing in an insulin pump.

1. Regular human insulin (Humulin R U-100): “Do not mix HUMULIN R with insulin preparations other than HUMULIN N.” Humulin R U-100 US prescribing information (DailyMed version 35, effective June 16, 2026), read October 27, 2026. Decides 1 may-mix cell, 5 do-not-mix cells.
2. NPH insulin (Humulin N): “HUMULIN N may be mixed with HUMULIN R or HUMALOG before injection.” Humulin N US prescribing information (DailyMed version 50, effective December 19, 2025), read October 5, 2026. Decides 2 may-mix cells.
3. Insulin lispro (Humalog U-100): “HUMALOG U-100 may be mixed with NPH insulin preparations ONLY” Humalog U-100 US prescribing information (DailyMed version 87, effective June 16, 2026), read October 27, 2026. Decides 1 may-mix cell, 5 do-not-mix cells.
4. Insulin aspart (NovoLog): “NOVOLOG may only be mixed with NPH insulin preparations.” NovoLog US prescribing information (DailyMed version 34, effective February 28, 2023), read October 5, 2026. Decides 1 may-mix cell, 5 do-not-mix cells.
5. Insulin glulisine (Apidra): “Do not mix APIDRA for subcutaneous injection with insulins other than NPH insulin.” Apidra US prescribing information (DailyMed version 28, effective November 25, 2025), read October 5, 2026. Decides 1 may-mix cell, 5 do-not-mix cells.
6. Insulin glargine (Lantus): “Do not dilute or mix LANTUS with any other insulin or solution.” Lantus US prescribing information (DailyMed version 35, effective June 2, 2025), read October 27, 2026. Decides 12 do-not-mix cells.
7. Insulin degludec (Tresiba): “DO NOT dilute or mix TRESIBA with any other insulin or solution.” Tresiba US prescribing information (DailyMed version 14, effective July 1, 2022), read October 5, 2026. Decides 12 do-not-mix cells.
8. Pramlintide (Symlin): “SYMLIN and insulin must not be mixed and must be administered as separate injections” Symlin US prescribing information (DailyMed version 18, effective December 18, 2019), read October 5, 2026. Decides 7 do-not-mix cells.
9. Semaglutide (Ozempic): “When using OZEMPIC with insulin, instruct patients to administer as separate injections and to never mix the products.” Ozempic US prescribing information (DailyMed version 20, effective June 1, 2026), read October 5, 2026. Decides 7 do-not-mix cells.
10. Tirzepatide (Mounjaro): “When using MOUNJARO with insulin, administer as separate injections and never mix.” Mounjaro US prescribing information (DailyMed version 40, effective August 27, 2026), read October 5, 2026. Decides 7 do-not-mix cells.
11. Liraglutide (Victoza): “When using VICTOZA with insulin, administer as separate injections. Never mix.” Victoza US prescribing information (DailyMed version 31, effective October 14, 2025), read October 5, 2026. Decides 7 do-not-mix cells.
12. Dulaglutide (Trulicity): “When using TRULICITY with insulin, administer as separate injections and never mix.” Trulicity US prescribing information (DailyMed version 62, effective June 16, 2026), read October 5, 2026. Decides 7 do-not-mix cells.
13. Exenatide (Byetta): “When using BYETTA with insulin, administer as separate injections and never mix.” Byetta US prescribing information (DailyMed version 26, effective September 2, 2025), read October 5, 2026. Decides 7 do-not-mix cells.

A published study behind one of the label answers:

• Insulin glargine (Lantus) + Insulin lispro (Humalog U-100): In 11 young people with type 1 diabetes, giving lispro and glargine as one mixed injection flattened and delayed lispro's early action compared with separate injections (time to peak glucose-lowering effect 209 against 116 minutes). Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care. 2010;33(5):1009-12. PMID: 20150302

Entries: Regular human insulin, NPH insulin, Insulin lispro, Insulin aspart, Insulin glulisine, Insulin glargine, Insulin degludec, Pramlintide, Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Exenatide.

The research grid's one label: Forzinity (elamipretide), Forzinity (elamipretide) US prescribing information (DailyMed version 10, effective December 10, 2025), read October 5, 2026.

Why the research grid is almost all unknown

Mixing two peptides in one vial is a formulation question: each has its own preferred acidity, salt form and stability, and a combination can change how either one dissolves, degrades or is absorbed. Labels answer it for the approved products above, sometimes with a study behind the answer (pramlintide's label says mixing it with insulin can alter the pharmacokinetics of both). For research peptides nobody has published that work. A 2026 review found that even BPC-157, among the most used, has no validated formulation and no formal excipient compatibility studies. Mateescu DM, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. PMID: 42198317 Our searches for mixing or compatibility studies of these peptides:

• PubMed, 2026-10-27: (compatibility OR "same syringe" OR admixture OR coformulation) AND (BPC-157 OR "thymosin beta 4" OR ipamorelin OR CJC-1295 OR sermorelin OR tesamorelin OR GHK-Cu OR bremelanotide OR semax OR selank) returned 10 records, 0 of them a mixing or compatibility study of the peptides searched.
• PubMed, 2026-10-27: (compatibility OR "same syringe" OR admixture OR "mixed with") AND (semaglutide OR tirzepatide OR retatrutide OR "thymosin alpha 1" OR elamipretide OR "melanotan II" OR epitalon OR "MOTS-c" OR KPV) AND (stability OR physicochemical) returned 4 records, 0 of them a mixing or compatibility study of the peptides searched.

Products sold as pre-mixed blends are a related question: see the blends and stacks hub for what has been studied about each mix.

This chart describes what labels and studies say. It is not medical advice and not an instruction to obtain or use any compound; ask a pharmacist before mixing anything in one syringe.